The FDA has granted Biotronik approval for its implantable cardioverter defibrillator that uses advanced sensors and the company's LinoxsmartS DX lead to allow doctors to monitor and detect atrial arrhythmias with just one lead. The device, called Lumax 740 DX System, is targeted for implantation in the U.S. starting late this month or early next month.
Biotronik wins FDA nod for single-lead, atrial-sensing ICD
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|